Abacus Life, Inc. (NASDAQ:ABL - Get Free Report) Director Adam Samuel Gusky purchased 3,000 shares of the stock in a transaction on Friday, December 13th. The stock was acquired at an average cost of $7.85 per share, with a total value of $23,550.00. Following the completion of the purchase, the director now directly owns 52,085 shares of the company's stock, valued at $408,867.25. The trade was a 6.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
Adam Samuel Gusky also recently made the following trade(s):
- On Monday, December 16th, Adam Samuel Gusky acquired 7,000 shares of Abacus Life stock. The stock was bought at an average price of $7.72 per share, for a total transaction of $54,040.00.
- On Monday, December 9th, Adam Samuel Gusky bought 6,000 shares of Abacus Life stock. The shares were bought at an average price of $7.94 per share, with a total value of $47,640.00.
- On Friday, December 6th, Adam Samuel Gusky purchased 2,126 shares of Abacus Life stock. The stock was bought at an average cost of $7.93 per share, for a total transaction of $16,859.18.
- On Friday, November 22nd, Adam Samuel Gusky acquired 18,241 shares of Abacus Life stock. The shares were bought at an average cost of $7.54 per share, with a total value of $137,537.14.
Abacus Life Stock Performance
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research | Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks.
Today, it’s probably the most popular stock in the world.
I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.
Shares of ABL opened at $7.86 on Tuesday. The company has a 50-day simple moving average of $8.63 and a two-hundred day simple moving average of $9.42. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.29 and a quick ratio of 1.29. The firm has a market capitalization of $665.58 million, a PE ratio of -43.67 and a beta of 0.13. Abacus Life, Inc. has a one year low of $7.07 and a one year high of $13.25.
Abacus Life (NASDAQ:ABL - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.06. The company had revenue of $28.15 million during the quarter, compared to analysts' expectations of $26.08 million. Abacus Life had a positive return on equity of 12.88% and a negative net margin of 11.65%. During the same quarter last year, the business posted $0.01 EPS. On average, analysts anticipate that Abacus Life, Inc. will post 0.64 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on ABL shares. Northland Securities assumed coverage on shares of Abacus Life in a research note on Thursday, October 24th. They issued an "outperform" rating and a $13.50 target price on the stock. B. Riley upped their price objective on shares of Abacus Life from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Monday, November 25th. B. Riley Financial reissued a "buy" rating and issued a $16.00 target price on shares of Abacus Life in a research note on Friday, August 30th. Piper Sandler reaffirmed an "overweight" rating and set a $13.00 price target (up previously from $12.00) on shares of Abacus Life in a research report on Friday, November 8th. Finally, Northland Capmk upgraded Abacus Life to a "strong-buy" rating in a report on Thursday, October 24th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Abacus Life presently has an average rating of "Buy" and an average target price of $14.70.
Read Our Latest Report on Abacus Life
Institutional Trading of Abacus Life
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Franklin Resources Inc. boosted its position in shares of Abacus Life by 3.6% in the 3rd quarter. Franklin Resources Inc. now owns 437,733 shares of the company's stock worth $4,382,000 after purchasing an additional 15,308 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Abacus Life by 439.6% in the third quarter. Geode Capital Management LLC now owns 171,917 shares of the company's stock worth $1,741,000 after acquiring an additional 140,054 shares in the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Abacus Life in the third quarter worth $614,000. Royce & Associates LP increased its holdings in shares of Abacus Life by 35.0% during the third quarter. Royce & Associates LP now owns 297,000 shares of the company's stock valued at $3,006,000 after acquiring an additional 77,000 shares in the last quarter. Finally, Curi RMB Capital LLC raised its position in shares of Abacus Life by 2.4% in the 3rd quarter. Curi RMB Capital LLC now owns 550,000 shares of the company's stock worth $5,566,000 after purchasing an additional 12,765 shares during the last quarter.
About Abacus Life
(
Get Free Report)
Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
